Abstract

To evaluate the pharmacokinetics of 2,3-dimethylquinoxaline using web server (absorption, distribution, metabolism, and excretion), safety profile. Moreover, to assess the efficacy of 2,3-dimethylquinoxaline (a natural quinoxaline derivative) in vitro and in vivo. The absorption, distribution, metabolism, and excretion of 2,3-dimethylquinoxaline were predicted using the web servers Swiss absorption, distribution, metabolism, and excretion and ProTox-II, respectively. In vitro efficacy against Madurella mycetomatis and a wide range of other pathogenic fungi was determined by microdilution assay. In vivo activity was evaluated using a topical gel (1 %) in the Bagg Albino mice eumycetoma model and an oral candidiasis model. 2,3-dimethylquinoxaline showed favourable absorption, distribution, metabolism, and excretion drug-likeness features and a high safety profile. It inhibited Madurella mycetomatis at a minimum inhibitory concentration of 312 µg/ml and exhibited potent in vitro activity against a range of other fungi, including Cryptococcus neoformans (minimum inhibitory concentration=9 µg/ml) and Candida tropicalis is (minimum inhibitory concentration=1.125 µg/ml). In vivo, 2,3-dimethylquinoxaline gel was effective in treating both skin Madurella mycetomatis infection and oral candidiasis. 2,3-dimethylquinoxaline is a promising natural antifungal drug with the potential to treat eumycetoma and other fungal infections.